Modern CEO says its coronavirus vaccine won’t be ready until spring of next year

Modern CEO Stephen Banksel said Wednesday that his company Coronavirus According to a report, the vaccine will not be ready for widespread public distribution until the spring of next year. The drugmakers also will not seek emergency authorization for vaccines for medical personnel and other at-risk individuals as soon as November 25, he told the Financial Times.

Speaking at a health conference on Wednesday, Bansell said that the moderns would not be ready for Food and Drug Administration approval for the vaccine for use in the general population at least until the end of January. If the vaccine proves to be safe and effective, approval is unlikely until late April or early April.

“I think it’s late [first quarter], soon [second quarter] According to the FT, Bansell said, “Approval is a reasonable timeline based on what we find from our vaccines.”

A spokesperson for Moderna confirmed Bansell’s remarks at the conference that the company expects to have enough vaccine test data by November 25 to apply with the FDA for Emergency Use Authorization.

The timeline is a setback for Modern, who said Earlier this month On November 1, it may seek emergency authorization for the vaccine. It is also a blow to claims by President Donald Trump, which he repeated in his debate with Joe Biden on Tuesday, that a vaccine could be ready in a matter of weeks, or before the November 3 presidential election.

Trump defends his coronavirus response


“We are weeks away from a vaccine,” Mr. Trump said Tuesday night during the first presidential debate with Biden. Mr Trump’s statement was in response to a question by moderator Chris Wallace that he disagreed with the prediction by the head of the US Center for Disease Control and Prevention that no vaccine would be ready until next summer.

“I’ve talked to Pfizer, I’ve talked to all the people you have to speak to – Modern, Johnson & Johnson and others. They can go much further than that very fast,” Mr. Trump said.

Morden shares from $ 4 to more than $ 70 a share on the news of its revised timeline. Modern did not respond to a request for comment.

Seven potential coronavirus vaccines are now undergoing late-stage trials, although more than 170 potential treatments are under development. According to Deutsche Bank analysts, about a third of vaccine candidates usually make it through all three stages of testing.


Leave a Reply

Your email address will not be published.